The effects of combination canagliflozin and glucagon-like peptide-1 receptor agonist therapy on intermediate markers of cardiovascular risk in the CANVAS program
Clare Arnott, Brendon L. Neuen, Hiddo J.L. Heerspink, Gemma A. Figtree, Mikhail Kosiborod, Carolyn S.P. Lam, Christopher P. Cannon, Norman Rosenthal, Wayne Shaw, Kenneth W. Mahaffey, Meg Jardine, Vlado Perkovic, Bruce Neal
Topics & Concepts
MedicineCanagliflozinInternal medicineType 2 diabetesPlaceboDiabetes mellitusAdverse effectGlucagon-like peptide 1 receptorBody mass indexGlucagon-like peptide-1EndocrinologyRandomized controlled trialAgonistGastroenterologyReceptorPathologyAlternative medicineDiabetes Treatment and ManagementPancreatic function and diabetesDiabetes Management and Research